Our Solutions Portfolio

Biosimilars are biologic medical products highly similar to already approved reference biologics. They are developed to offer cost-effective alternatives for expensive biologics, addressing critical needs in oncology, autoimmune diseases, and diabetes. Unlike generics, biosimilars require advanced manufacturing and rigorous clinical testing to ensure therapeutic equivalence.

The global biosimilars market is expected to grow at a CAGR of 25-28% from 2023 to 2030, driven by:

1. Patent Expirations: Major biologics such as adalimumab (Humira) are coming off-patent, creating opportunities for biosimilar entrants (Coghlan et al., 2021).
2. Rising Healthcare Costs: Governments and payers in regions like SEA, MEA, and LATAM are adopting biosimilars to expand patient access and achieve cost savings (Moorkens et al., 2016).
3. Increasing Acceptance: Physician and patient trust in biosimilars is improving, supported by clinical evidence of safety and efficacy (Reilly, 2019).

Monoclonal antibody (mAb) biosimilars target cancers such as breast, colorectal, and hematological malignancies.

Southeast Asia (SEA):

• Access Barriers:
  • High costs and limited local production facilities hinder uptake of biosimilar mAbs like trastuzumab and rituximab (Moorkens et al., 2016).
• Market Drivers:
  • Governments in Thailand and Malaysia are encouraging biosimilar adoption through tendering processes and price negotiations.
  • 
    

Middle East and Africa (MEA):

• Availability:
  • Wealthier Gulf countries are adopting biosimilar oncology mAbs, but low-income regions face limited access.
• Potential:
  • Policies to incentivize biosimilar use, such as price ceilings, are gaining traction (Requena-Méndez et al., 2020).

Latin America (LATAM):

• Adoption Trends:
  • Countries like Brazil and Argentina are integrating oncology biosimilars into public health systems, but regional disparities in adoption persist.
• Savings:
  • Biosimilar mAbs have reduced treatment costs by 30-40% in high-use areas (Barcina Lacosta et al., 2022).

Eastern Europe:

• Increased Access:
  • EU harmonization of biosimilar approval processes has improved access to mAbs in countries like Poland and Hungary.
• Challenges:
  • Non-EU nations like Ukraine rely on imports, delaying patient access (Inotai et al., 2018).

Insulin biosimilars are emerging as affordable alternatives for diabetes management.

Southeast Asia (SEA):

• Adoption:
  • Limited uptake due to physician skepticism and fragmented healthcare infrastructure (Davies et al., 2017).
• Emerging Trends:
  • Indonesia and the Philippines are incorporating biosimilar insulins into national diabetes programs.

Middle East and Africa (MEA):

• Access Disparities:
  • Biosimilar insulins are available in high-income countries like Saudi Arabia but remain inaccessible in low-income regions.
• Affordability:
  • Price reductions of 20-30% have improved access where adoption policies are in place (Davies et al., 2017).

Latin America (LATAM):

• Cost Savings:
  • Biosimilar insulins have reduced treatment costs by 25% in Argentina and Brazil, increasing affordability for low-income patients.
• Barriers:
  • Limited provider awareness and distribution networks hinder broader adoption.

Eastern Europe:

• Growing Acceptance:
  • Biosimilar insulins are gaining traction in Hungary and Poland, supported by favorable pricing policies.
• Challenges:
  • Physician resistance to switching from originator insulins remains a significant barrier (Inotai et al., 2018).

Biosimilars for tumor necrosis factor (TNF)-alpha inhibitors such as infliximab and adalimumab are transforming autoimmune disease treatment.

Southeast Asia (SEA):

• Limited Availability:
  • Biosimilars for rheumatoid arthritis and inflammatory bowel disease (IBD) are underutilized due to cost concerns and low awareness.
• Future Potential:
  • Regional partnerships to manufacture biosimilars locally are under discussion.

Middle East and Africa (MEA):

• Access Gaps:
  • Most autoimmune disease biosimilars are unavailable outside Gulf countries.
• Market Trends:
  • Awareness campaigns are improving uptake in urban centers.

Latin America (LATAM):

• Cost Savings:
  • Biosimilar TNF inhibitors have reduced treatment costs by up to 50% in Brazil, increasing patient access.
• Challenges:
  • Rural areas still lack infrastructure for widespread adoption.

Eastern Europe:

• Adoption Trends:
  • EU member states report rapid uptake of TNF biosimilars due to reimbursement policies.
• Challenges:
  • Non-EU countries face slower adoption due to regulatory delays.

    1. Physician Acceptance:

• Skepticism regarding therapeutic equivalence limits adoption, especially for insulins and TNF biosimilars.

    2. Cost and Access:

• Pricing and reimbursement policies play a critical role in biosimilar penetration, with significant disparities across regions.

    3. Infrastructure:

• Manufacturing and distribution capacity must be expanded in SEA, MEA, and LATAM to meet growing demand.

Biosimilars represent a transformative opportunity to reduce healthcare costs and expand access, especially in underserved regions. However, overcoming regulatory barriers, improving physician education, and ensuring consistent pricing policies are essential to unlocking their full potential.